Navigation Links
Gamida Cell Announces Feasibility Study With Weill Cornell Medical College

JERUSALEM, Israel, December 2 /PRNewswire/ -- Gamida Cell announced today a feasibility study evaluating the preclinical (animal study) safety and efficacy of a gene therapy product which combines technology from Weill Cornell Medical College and Gamida Cell. The product may have potential to treat inherited anemias such as Cooley's Anemia.

Gamida Cell is developing a series of technologies to expand, ex vivo, populations of stem/progenitor cells. The company's lead product, StemEx(R), comprised of expanded populations of adult stem cells derived from umbilical cord blood (UCB), is used today as an experimental treatment for blood cancers like leukemia and lymphoma (see ExCell trial at

Using lentivirus-based gene transfer, Weill Cornell is researching methods to successfully transfer intactglobin genes, coding for functional hemoglobin proteins, into hematopoietic (blood) stem cells with the goal of developing a cure for beta-thalassemia, generally known as Cooley's anemia and Sickle cell anemia. These are the most commonly inherited diseases.

"The current treatment for Cooley's and sickle cell anemia is chronic blood transfusion, which is used to prevent an otherwise likely fatal outcome. Stem cell-based gene transfer, an ex vivo procedure commonly known as transduction, offers a potential means to cure these diseases through the permanent integration of potentially therapeutic genes into the hematopoietic stem cells of the patient. The limitation of this therapy is the low number of transduced stem cells. Expanding the number of transduced stem cells in vitro before reinfusion offers the possibility of creating a more effective therapy and consequently, a potential cure. Using Gamida Cell's expansion technology, we hope to transfer a substantively increased number of stem cells, transduced with an intact globin gene coding for a functional hemoglobin protein, through an expanded population of hematopoietic stem cells, large enough to make a therapeutic impact," said Dr. Stefano Rivella, assistant professor of genetic medicine in pediatrics at Weill Cornell Medical College.

"This initiative is of great importance as it could lead to some revolutionary breakthrough science. It also demonstrates yet another example of how Gamida Cell's proprietary technology can complement other existing technologies to potentially find cures for deadly and chronic diseases," said Tony Peled, chief scientific officer and vice president of research & development of Gamida Cell.

In the event the effort is successful, Gamida Cell and Weill Cornell will have the option to enter into further co-development and commercialization agreements.

About Gamida Cell

Gamida Cell Ltd. is a world leader in stem cell expansion technologies and therapeutic products. The company is developing a pipeline of products in stem cell transplantation and in tissue regeneration to effectively treat debilitating and often fatal illnesses such as cancer, hematological, autoimmune and ischemic diseases. Gamida Cell's therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood and bone marrow, which are expanded in culture. Gamida Cell was successful in translating these proprietary expansion technologies into robust and validated manufacturing processes under GMP. Gamida Cell's flagship product, StemEx, is now being studied as a therapy for patients with blood cancers in an international pivotal trial at leading transplant centers in the U.S., Europe and Israel. StemEx has orphan drug designation in the U.S. and in Europe. Gamida Cell's current shareholders include: Elbit Imaging, Biomedical Investment, Israel Healthcare Venture, Teva Pharmaceutical Industries, Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: For information regarding the ExCell study:

    Press contact:
    Marjie Hadad
    Media Liaison/IR
    Gamida Cell

SOURCE Gamida Cell LTD

SOURCE Gamida Cell LTD
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Gamida Cell and Cellerix Partner on Feasibility Study
2. CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida
3. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
4. Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia
5. PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT
6. Ohio Capital Fund Announces Sponsorship of Minority Business Conference
7. Cadient Interactive Announces the Launch of HATCH Consulting Services
8. Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics
9. The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinsons Disease Treatments
10. ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ
11. Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)
Post Your Comments:
(Date:10/9/2015)... Oct. 9, 2015  Pulmatrix, Inc., (NASDAQ: PULM ) ... investor conferences. th Annual BIO Investor ... (2:00 pm EDT). --> th Annual ... am PDT (2:00 pm EDT). --> Pulmatrix ... Growth Stock Conference on Thursday, October 15, 2015 at 8:30 ...
(Date:10/8/2015)... 2015  Sorrento Therapeutics, Inc. (NASDAQ:  SRNE; Sorrento), ... cancer and associated pain, announced today that Dr. Henry Ji, ... at the Aegis Capital Corporation 2015 Growth Conference ... Corporation 2015 Growth ConferenceDate:Friday, October 9, 2015Time:10:00 to ... The Wynn in Las Vegas, NV , ...
(Date:10/8/2015)... , October 8, 2015 ... .   --> Goldman Small Cap ... the small cap and microcap sectors, announced today ... report on PharmaCyte Biotech, Inc. (OTCQB - PMCB), ... on developing and preparing treatments for cancer and ...
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
Breaking Biology Technology:
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), today announced that ... units at an issue price of US $1.20 for gross ... one common share and one half common share purchase warrant. Each whole ... until March 10, 2015 . , ...
... March 10 Bone Biologics, Inc. announced today ... shares from the Musculoskeletal Transplant Foundation (MTF). MTF now ... financing, MTF also provided a line of credit to ... by MTF that have allowed Bone Biologics, Inc. to ...
... ... ... ... ...
Cached Biology Technology:
(Date:9/28/2015)... 28, 2015 CLEAR, the leading ... expedited traveler service is coming to Austin-Bergstrom ... bringing a frictionless experience, serious speed and ... "CLEAR offers our travelers an expedited security ... Jim Smith , Executive Director, Austin-Bergstrom ...
(Date:9/28/2015)... JOSE, Calif. , Sept. 28, 2015 ... of human interface solutions, today announced that Lenovo has ... touch fingerprint sensor, FS4202, for its latest smartphone, the ... secure, password-free access to unlock the device and provide ... The feature-rich Natural ID FS4202 sensor ...
(Date:9/10/2015)... This report provides detailed descriptions of the sensor types ... types that will dominate in the future. Many product ... technology hype curve in the last five years before ... all of them is the prominence of sensor options ... Sensors collect data about the physical and chemical properties ...
Breaking Biology News(10 mins):
... Society today commends President Obama,s decision to sign a ... scientific evidence is used in the development of solutions ... memorandum rightly places science at the forefront of informing ... of solutions to issues such as enhancing energy security, ...
... of proteins, the molecular machines that drive all life, also ... study, in the journal Structure , reveals that after ... of innovation. The active regions of many proteins, called domains, ... host of structures that had never been seen before. This ...
... to treat critical limb ischemia in peripheral arterial ... thwarted by restenosis (the re-narrowing of the artery ... need for repeat treatments and the continued progression ... and amputation. Interventional radiologists have been studying a ...
Cached Biology News:
ma. plate stack height 70mm...
Rotor for four tube-loaded buckets; ma RCF 2550g; sold without buckets...
CQCS kit for etra KR 4i , (other units)....
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
Biology Products: